Evidence map›Paper›PMID 37759276›Full record

ArticleNeurological research and practice2023

No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache.

Laura de Boni, Alexandru Odainic, Natalie Gancarczyk, Luisa Kaluza, Christian P Strassburg, Xenia A K Kersting, Ullrich Wüllner, Susanne V Schmidt, Gabor C Petzold

Open access · diamondAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Laura de BoniInstitute of Aerospace Medicine, German Aerospace Center, Cologne, Germany.
Alexandru OdainicInstitute of Innate Immunity, University Hospital Bonn, Bonn, Germany.
Natalie GancarczykDivision of Vascular Neurology, Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Luisa KaluzaDivision of Vascular Neurology, Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Christian P StrassburgDepartment of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
Xenia A K KerstingDepartment of Psychiatry and Psychotherapy, University Hospital Mainz, Mainz, Germany.
Ullrich WüllnerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Susanne V SchmidtInstitute of Innate Immunity, University Hospital Bonn, Bonn, Germany.
Gabor C PetzoldDivision of Vascular Neurology, Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. gabor.petzold@ukbonn.de.
University Hospital Bonn · DEDeutsches Zentrum für Luft- und Raumfahrt e. V. (DLR) · DEJohannes Gutenberg University Mainz · DE

Funding

HORIZON EUROPE Excellent Science 101057775
6 · The paper itself

Abstract

Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation.

Indexed as

BiomarkersCerebrospinal fluidGFAPHeadacheNfLPost-acute sequelae of SARS-CoV-2 infectionpost-COVID-19TauUCH-L1

Identifiers

PMID37759276
PMCPMC10536703
OpenAlexW4387079745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.